Vaxcyte, Inc. $PCVX Shares Sold by Algert Global LLC

Key Points

• Algert Global LLC has reduced its stake in Vaxcyte, Inc. by 23.1%, holding 56,179 shares worth approximately $2.12 million as of the latest SEC filing.
• Other institutional investors increased their positions in Vaxcyte significantly, with Parallel Advisors LLC raising its investment by 203.6% and IFP Advisors Inc by 376.4% during the first quarter.
• Vaxcyte's stock currently holds a consensus rating of Buy from analysts, with an average price target of $136.50, despite the company posting a quarterly EPS loss of ($1.22).

Algert Global LLC decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 23.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 56,179 shares of the company's stock after selling 16,890 shares during the quarter. Algert Global LLC's holdings in Vaxcyte were worth $2,121,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PCVX. Raymond James Financial Inc. grew its stake in shares of Vaxcyte by 10.7% in the 1st quarter. Raymond James Financial Inc. now owns 293,134 shares of the company's stock valued at $11,069,000 after buying an additional 28,430 shares during the period. Aberdeen Group plc grew its stake in shares of Vaxcyte by 17.8% in the 1st quarter. Aberdeen Group plc now owns 264,737 shares of the company's stock valued at $9,996,000 after buying an additional 39,913 shares during the period. Fox Run Management L.L.C. grew its stake in shares of Vaxcyte by 758.1% in the 1st quarter. Fox Run Management L.L.C. now owns 34,228 shares of the company's stock valued at $1,292,000 after buying an additional 30,239 shares during the period. E Fund Management Co. Ltd. increased its stake in Vaxcyte by 17.6% during the first quarter. E Fund Management Co. Ltd. now owns 12,319 shares of the company's stock worth $465,000 after acquiring an additional 1,840 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in Vaxcyte by 7,023.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 21,015 shares of the company's stock valued at $794,000 after purchasing an additional 20,720 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Up 1.0%

NASDAQ:PCVX traded up $0.30 on Wednesday, reaching $30.55. The company's stock had a trading volume of 2,046,811 shares, compared to its average volume of 1,465,749. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The stock has a 50 day moving average price of $33.44 and a 200 day moving average price of $43.52. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of -7.43 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the business earned ($1.10) earnings per share. Equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.